| Name | Title | Contact Details |
|---|---|---|
Sanjeeve Bala |
Vice President, US Regulatory Affairs | Profile |
Mark Dizon |
Assistant General Counsel, Chief Compliance Officer | Profile |
Mark Dizon |
Assistant General Counsel and Chief Compliance Officer | Profile |
Jamie Gillette |
Senior Director, Regulatory Affairs | Profile |
Sophia Ng |
Sr. Director and Sr. Corporate Counsel | Profile |
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
As a pioneer in the development of automated validation software solutions, ValGenesis leads the way with a unique paperless validation process that tracks the validation status of any GxP system in real time. With years of development and refinement in place, ValGenesis is the first to offer users real-time paperless validation via electronic execution thereby minimizing ineffectiveness and maximizing efficiency. ValGenesis automates and manages the validation life cycle and provides real time validation status of any system corporate wide.
Amylin Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.